Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer

ABSTRACT

The 2024 ASCO Genitourinary Cancer Symposium, this year celebrating the 20th anniversary, delved into key advancements in urothelial carcinoma (UC) and prostate cancer (PC). For UC, insights emerged from adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and from the efficacy of the EV-302 study of enfortumab vedotin +pembrolizumab in the metastatic setting. In PC, adjuvant therapy with high-dose radiotherapy schedules plus long-t erm ADT was explored. In metastatic castration-resistant PC, highlights included a novel combo (cabozantinib+atezolizumab) for poor prognosis patients; confirmed benefits of ARSI+PARPi in BRCA-mutated patients; and safety considerations for ARSI treatments. The symposium continued its role as an indispensable platform for shaping specialized oncological care.

KEYWORDS:

• Urothelial carcinoma
• prostate cancer
• 2024 ASCO GU
• mCRPC
• mUC
• MIBC

Declaration of interest

C Ciccarese reports being on the advisory board, invited speaker, meetings traveling: IPSEN, Merck Sharp & Dohme, Astellas, AstraZeneca, Pfizer, Janssen, and Bristol Myers Squibb, Novartis, EISAI. R Iacovelli reports being on the advisory board, invited speaker, meetings traveling: Pfizer, Janssen, Sanofi, IPSEN, Merck, Sharp & Dohme, Novartis, AstraZeneca, Astellas, and Bristol Myers Squibb, EISAI. G Tortora reports being a consultant for BMS, MSD, Astra Zeneca, Servier, Merck Serono, Dompé. R Berardi reports being an advisory board, invited speaker, meetings traveling: AstraZeneca, Boehringer, MSD, Lilly, Roche, Amgen, GSK, Eisai, BMS.

Reviewer disclosures

A reviewer on this manuscript has disclosed being an Advisory Board member for EMD Serono, BMS, Merck, Seattle Genetics/Astellas, Janssen, Bicycle Therapeutics, Pfizer, Gilead, Scholar Rock, Eli Lilly/Loxo Oncology, Vial, PrecisCa, Atkis, Kura Oncology, Daiichi-Sankyo. Consultant/Scientific Advisory Board (SAB): Syapse, Merck, Servier, Syncorp. Research Support to institution: EMD Serono, Jazz Therapeutics, BMS, A speaker for Seagen, Gilead, Natera, Exelixis, Janssen, Astellas, Bayer, Aveo, Merck, Pfizer. CME-certified speaking for Research to Practice, PeerView Institute, Ideology Health, IBCU/Grand Rounds in Urology. Data safety monitoring committee (honorarium) for Mereo. Spouse employed by Myriad. Received writing/editor fees from Uptodate, Practice Update, Onviv, DAVA Oncology. Travel: BMS, Astellas. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.

Additional information

Funding

This paper was not funded.